


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

### Listing of Claims:

1. (Currently amended) A compound of formula I




wherein:

R is (C<sub>3-5</sub>)alkyl, di(C<sub>1-4</sub>)alkoxymethyl, (C<sub>3-6</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl or benzyl optionally substituted in the aromatic ring by one to three radicals selected from the group consisting of (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy and halo,

R<sub>1</sub> is hydrogen or hydroxy,

R<sub>2</sub> is a group of formula



wherein R<sub>a</sub> is (C<sub>1-4</sub>)alkoxy, and

R<sub>3</sub> is hydrogen or (C<sub>1-4</sub>)alkyl,

or a salt thereof;

wherein the compound of formula I is selected from the group consisting of:

{3-[(6-methoxy-3-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(cyclohexylmethyl)-phosphinic acid;

{3-[(2-methoxy-4-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(cyclohexylmethyl)-phosphinic acid;

{3-[(6-methoxy-3-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(benzyl)-phosphinic acid;

{3-[(2-methoxy-4-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(benzyl)phosphinic acid;

{3-[6-methoxy-3-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(diethoxy-methyl)-phosphinic acid;

{3-[2-methoxy-4-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(diethoxy-methyl)-phosphinic acid;

{2-(S)-hydroxy-3-[6-oxo-1,6-dihydro-pyridin-3-ylmethyl)-amino]-propyl}-(cyclohexylmethyl)-phosphinic acid;


{2-(S)-hydroxy-3-[(2-oxo-1,2-dihydro-pyridin-4-ylmethyl)amino]-propyl}-(cyclohexylmethyl)-phosphinic acid;

{2-(S)-hydroxy-3-[(6-oxo-1,6-dihydro-pyridin-3-ylmethyl)-amino]-propyl}-(benzyl)-phosphinic acid; and

{2-(S)-hydroxy-3-[(2-oxo-1,2-dihydro-pyridin-4-ylmethyl)-amino]-propyl}-(benzyl)-phosphinic acid.

2. (Currently amended) [[A]] The compound of claim 1, which is {2-(S)-hydroxy-3-[(6-oxo-1,6-dihydro-pyridin-3-ylmethyl)-amino]-propyl}-(cyclohexylmethyl)-phosphinic acid or a salt thereof ~~; in free base or salt form.~~

3. (Currently amended) A process for the production of [[a]] the compound of formula I as defined in claim 1 ~~; in free base or salt form~~, the process comprising which comprises, in a compound of formula II



wherein R and R<sub>2</sub> are as defined in claim 1, R<sub>4</sub> is a hydroxy-protecting group, R<sub>5</sub> is hydrogen or protected hydroxyl, and R<sub>6</sub> is R<sub>3</sub> as defined in claim 1 or an amino-protecting group, or in a salt thereof,

freeing the hydroxy group by replacing the hydroxy-protecting group R<sub>4</sub> by hydrogen and, where appropriate, freeing the hydroxy group R<sub>1</sub> from the protected hydroxy group R<sub>5</sub>, and

removing the amino-protecting group R<sub>6</sub> and,

~~——— if desired, converting a resulting compound into a different compound of formula I, separating a mixture of isomers into its components and/or converting a salt into the corresponding free compound or vice versa.~~

4. (Currently amended) ~~[[A]]~~ The compound of claim 1, wherein the salt is a pharmaceutically acceptable salt in free base or pharmaceutically acceptable salt form, for use as a pharmaceutical.
5. (Currently amended): A pharmaceutical composition comprising ~~[[a]]~~ the compound of claim 4 1, in free base or pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent.
6. (Canceled)
7. (Canceled)
8. (New) A method for the treatment of epilepsy, cerebral insufficiency, cognition deficits, depression, schizophrenia, or anxiety in a subject in need of such treatment, the method comprising administering to the subject the compound of claim 1 or a pharmaceutically acceptable salt thereof.
9. (New) A method for the treatment of epilepsy of the “petit mal” type, cerebral insufficiency, depression or anxiety in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
10. (New) The compound of claim 1, wherein the compound is {3-[(6-methoxy-3-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(cyclohexylmethyl)-phosphinic acid or a salt thereof.
11. (New) The compound of claim 1, wherein the compound is {3-[(2-methoxy-4-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(cyclohexylmethyl)-phosphinic acid or a salt thereof.

12. (New) The compound of claim 1, wherein the compound is {3-[(6-methoxy-3-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(benzyl)-phosphinic acid or a salt thereof.
13. (New) The compound of claim 1, wherein the compound is {3-[(2-methoxy-4-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(benzyl)phosphinic acid or a salt thereof.
14. (New) The compound of claim 1, wherein the compound is {3-[6-methoxy-3-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(diethoxy-methyl)-phosphinic acid or a salt thereof.
15. (New) The compound of claim 1, wherein the compound is {3-[2-methoxy-4-pyridylmethyl)-amino]-2-(S)-hydroxy-propyl}-(diethoxy-methyl)-phosphinic acid or a salt thereof.
16. (New) The compound of claim 1, wherein the compound is {2-(S)-hydroxy-3-[(2-oxo-1,2-dihydro-pyridin-4-ylmethyl)amino]-propyl}-(cyclohexylmethyl)-phosphinic acid or a salt thereof.
17. (New) The compound of claim 1, wherein the compound is {2-(S)-hydroxy-3-[(6-oxo-1,6-dihydro-pyridin-3-ylmethyl)-amino]-propyl}-(benzyl)-phosphinic acid or a salt thereof.
18. (New) The compound of claim 1, wherein the compound is {2-(S)-hydroxy-3-[(2-oxo-1,2-dihydro-pyridin-4-ylmethyl)-amino]-propyl}-(benzyl)-phosphinic acid or a salt thereof.
19. (New) The process of claim 3, further comprising:  
  
converting a resulting compound into a different compound of formula I,  
  
separating a mixture of isomers into its components, or  
  
converting a salt of the compound into its corresponding free compound or vice-versa.